The University of Chicago Header Logo

Ezra Cohen

TitleASSOCIATE PROFESSOR
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA247551     (GUTKIND, JORGE SILVIO)Dec 1, 2019 - Nov 30, 2024
    NIH
    Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
    Role: Co-Principal Investigator
    R01CA226909     (COHEN, EZRA ;VARNER, JUDITH A)Apr 17, 2018 - Nov 30, 2028
    NIH
    Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
    Role: Co-Principal Investigator
    U01CA217885     (TAMAYO, PABLO)Sep 12, 2017 - Jul 31, 2022
    NIH
    A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
    Role: Co-Principal Investigator
    R21DE022454     (COHEN, EZRA)Aug 15, 2012 - Jul 31, 2014
    NIH
    Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms
    Role: Principal Investigator
    R01CA134633     (AHRENS, ERIC T)May 10, 2009 - May 31, 2022
    NIH
    Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
    Role: Co-Principal Investigator
    R21CA125000     (COHEN, EZRA)Sep 1, 2007 - Aug 31, 2010
    NIH
    Functional Infrared Imaging Predicts Radiation Mucositis
    Role: Principal Investigator
    R21CA112951     (COHEN, EZRA)Jun 6, 2005 - May 31, 2008
    NIH
    Rapamycin as an Antineoplastic Agent
    Role: Principal Investigator
    T32CA009566     (OLOPADE, OLUFUNMILAYO F.)Sep 5, 1987 - Jun 30, 2028
    NIH
    Basic Medical Research Training in Oncology
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Flanagan KC, Earls J, Hiken J, Wellinghoff RL, Ponder MM, McLeod HL, Westra WH, Vavinskaya V, Sutton L, Deichaite I, Macdonald OK, Welaya K, Wade J, Azzi G, Pippas AW, Slim J, Bank B, Sui X, Kossman SE, Shenkenberg TD, Alexander WL, Price KA, Ley J, Messina DN, Glasscock JI, Colevas AD, Cohen EEW, Adkins D, Duncavage EJ. Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study. J Immunother Cancer. 2024 Nov 03; 12(11). PMID: 39489541; PMCID: PMC11535711.
      Citations:    
    2. Dennis MJ, Pavlick DC, Kacew A, Wotman M, MacConaill LE, Jones SM, Pfaff KL, Rodig SJ, Eacker S, Malig M, Reister E, Piccioni D, Kesari S, Sehgal K, Haddad RI, Cohen E, Posner MR, Deichaite I, Hanna GJ. Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma. J Transl Med. 2024 Oct 22; 22(1):960. PMID: 39438862; PMCID: PMC11515687.
      Citations:    Fields:    Translation:HumansCells
    3. Vaidya P, Cohen EEW. Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence. Clin Cancer Res. 2024 Apr 01; 30(7):1232-1239. PMID: 37955563; PMCID: PMC10984792.
      Citations:    Fields:    Translation:Humans
    4. Yun KM, Cohen EEW. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncol Pract. 2024 Jul; 20(7):899-906. PMID: 38452309.
      Citations: 1     Fields:    Translation:Humans
    5. Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024 Mar; 199:113530. PMID: 38295556; PMCID: PMC11227881.
      Citations: 4     Fields:    Translation:Humans
    6. Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN, Lippman SM, Woo SB. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jan 01; 10(1):32-41. PMID: 37971722; PMCID: PMC10654930.
      Citations: 4     Fields:    Translation:Humans
    7. Madan S, Sinha S, Chang T, Gutkind JS, Cohen EEW, Schäffer AA, Ruppin E. Pan-Cancer Analysis of Patient Tumor Single-Cell Transcriptomes Identifies Promising Selective and Safe Chimeric Antigen Receptor Targets in Head and Neck Cancer. Cancers (Basel). 2023 Oct 08; 15(19). PMID: 37835579; PMCID: PMC10571718.
      Citations:    
    8. Flanagan KC, Earls J, Schillebeeckx I, Hiken J, Wellinghoff RL, LaFranzo NA, Bradley ZS, Babbitt J, Westra WH, Hsu R, Nadauld L, Mcleod H, Firth SD, Sharp B, Fuller J, Vavinskaya V, Sutton L, Deichaite I, Bailey SD, Sandulache VC, Rendo MJ, Macdonald OK, Welaya K, Wade JL, Pippas AW, Slim J, Bank B, Saccaro SJ, Sui X, Akhtar A, Balaraman S, Kossman SE, Sonnier SA, Shenkenberg TD, Alexander WL, Price KA, Bane CL, Ley J, Messina DN, Glasscock JI, Cohen EEW, Adkins DR, Duncavage EJ. Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma. J Cancer Res Clin Oncol. 2023 Nov; 149(15):14125-14136. PMID: 37552307; PMCID: PMC10590294.
      Citations: 1     Fields:    
    9. Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 06 13; 29(12):2210-2219. PMID: 37000164; PMCID: PMC10388696.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    10. Ahrens ET, Helfer BM, O'Hanlon CF, Lister DR, Bykowski JL, Messer K, Leach BI, Chen J, Xu H, Daniels GA, Cohen EEW. Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion. J Immunother Cancer. 2023 06; 11(6). PMID: 37339797; PMCID: PMC10314637.
      Citations: 3     Fields:    Translation:HumansCells
    11. Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722. PMID: 37182801; PMCID: PMC10696593.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    12. Faraji F, Cohen EEW, Guo TW. Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy. Transl Cancer Res. 2023 May 31; 12(5):1353-1358. PMID: 37304550; PMCID: PMC10248584.
      Citations: 1     
    13. Nathan CO, Hayes DN, Karrison T, Harismendy O, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Grilley-Olson J, Day T, Gillison M, Wade JL, Feldman L, Jha G, Kozloff M, O'Leary M, Worden FP, Cohen EEW, Flores JM. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048. PMID: 36194164; PMCID: PMC9722644.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    14. Zhao X, Cohen EEW, William WN, Bianchi JJ, Abraham JP, Magee D, Spetzler DB, Gutkind JS, Alexandrov LB, Cavenee WK, Lippman SM, Davoli T. Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity. Proc Natl Acad Sci U S A. 2022 11 22; 119(47):e2213835119. PMID: 36395141; PMCID: PMC9704728.
      Citations: 13     Fields:    Translation:Humans
    15. Dennis MJ, Sacco AG, Qi Y, Bykowski J, Pittman E, Chen R, Messer K, Cohen EEW, Gold KA. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2022 12; 135:106219. PMID: 36279618.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    16. Levy DA, Patel JJ, Nguyen SA, Nicholas Jungbauer W, Neskey DM, Cohen EEW, Paulos CM, Kaczmar JA, Knochelmann HM, Day TA. Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis. World J Otorhinolaryngol Head Neck Surg. 2022 Sep; 8(3):177-186. PMID: 36159902; PMCID: PMC9479482.
      Citations: 1     
    17. Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clin Cancer Res. 2022 03 15; 28(6):1157-1166. PMID: 34965944; PMCID: PMC9365346.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    18. Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914. PMID: 34862248; PMCID: PMC9311322.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    19. Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May; 18(14):1669-1678. PMID: 35172587.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    20. Jeong AR, Forbes K, Orosco RK, Cohen EEW. Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. J Otolaryngol Head Neck Surg. 2022 Feb 05; 51(1):5. PMID: 35123577; PMCID: PMC8818223.
      Citations: 5     Fields:    Translation:Humans
    21. Sacco AG, Cohen EEW. Inevitable Progress-Relying on the Immune System, Not Chance. Clin Cancer Res. 2022 02 01; 28(3):435-437. PMID: 34848533.
      Citations:    Fields:    Translation:Humans
    22. Saddawi-Konefka R, Simon AB, Sumner W, Sharabi A, Mell LK, Cohen EEW. Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Front Oncol. 2021; 11:738626. PMID: 34621678; PMCID: PMC8490924.
      Citations: 3     
    23. Kim SS, Sumner WA, Miyauchi S, Cohen EEW, Califano JA, Sharabi AB. Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021 11 15; 27(22):6075-6082. PMID: 34230025; PMCID: PMC8976464.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    24. Lee NY, Ferris RL, Cohen E, De Beukelaer S. Patient selection for immunotherapy in head and neck cancer - Authors' reply. Lancet Oncol. 2021 07; 22(7):e291-e292. PMID: 34197753.
      Citations:    Fields:    Translation:Humans
    25. Kato S, Cohen EEW. Did Everolimus Break the Rules? Clin Cancer Res. 2021 07 15; 27(14):3807-3808. PMID: 33986025.
      Citations: 1     Fields:    Translation:Humans
    26. Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 06; 22(6):883-892. PMID: 33989559.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    27. Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, Duvvuri U, Grandis JR, Califano JA, Cohen EEW, Gutkind JS. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383. PMID: 33888713; PMCID: PMC8062674.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    28. Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Chamois J, Hu C, Dunn LA, Dvorkin MV, Pavlov D, Thurm H, Cohen E, Teixeira MM, Lövey J, Rueda A, De Beukelaer S. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021 04; 22(4):450-462. PMID: 33794205.
      Citations: 188     Fields:    Translation:HumansCTClinical Trials
    29. Harrington KJ, Le Tourneau C, Licitra LF, Ahn MJ, Machiels JH, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW, Soulières D, Dinis J, Soria A, Mach N. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. J Natl Cancer Inst. 2021 02 01; 113(2):171-181. PMID: 32407532; PMCID: PMC7850527.
      Citations: 15     Fields:    Translation:Humans
    30. Lacas B, Carmel A, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Hitt R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Sharma A, Ruo Redda MG, Fountzilas G, Rovea P, Argiris A, Lee JW, Fortpied C, Harris J, Bourhis J, Blanchard P, Pignon JP, MACH-NC Collaborative Group, Landais C, Wolf G, Corvò R, Zakotnik B, Bensadoun RJ, Racadot S, Brizel D, Nagy ZT, Aupérin A. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021 03; 156:281-293. PMID: 33515668; PMCID: PMC8386522.
      Citations: 91     Fields:    Translation:Humans
    31. Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen EEW, Harrington K, Le Tourneau C, Licitra L, Burtness B, Swaby R, Soulières D. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2021 03; 34(3):532-541. PMID: 33239737.
      Citations: 40     Fields:    Translation:Humans
    32. Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification. Clin Cancer Res. 2021 02 01; 27(3):689-703. PMID: 33122346.
      Citations: 70     Fields:    Translation:HumansCells
    33. Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D, Cohen EEW, Radcliffe HS, Gumuscu B, Cheng J, Snyder W, Siu LL. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clin Cancer Res. 2020 10 01; 26(19):5153-5161. PMID: 32669371.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    34. Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL, Pérez-Ruiz E. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020 09 01; 126(17):3972-3981. PMID: 32557577; PMCID: PMC8266417.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    35. Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, Bykowski J, Ellison CA, Black LJ, Thompson PA, Callejas-Valera JL, Lee JH, Cohen EEW, Spanos WC. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. J Clin Oncol. 2020 07 20; 38(21):2427-2437. PMID: 32479189; PMCID: PMC7365766.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    36. Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clin Cancer Res. 2020 07 01; 26(13):3345-3359. PMID: 32193227; PMCID: PMC7334097.
      Citations: 76     Fields:    Translation:HumansAnimalsCells
    37. Haddad R, Cohen EEW, Venkatachalam M, Young K, Singh P, Shaw JW, Korytowsky B, Abraham P, Harrington KJ. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447. PMID: 31928375.
      Citations: 13     Fields:    Translation:Humans
    38. Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, Li P, Dechaphunkul A, Kumar V, Kamble K, Li W, Kandil A, Cohen EEW, Geng Y, Zografos E, Tang PZ. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Ann Oncol. 2019 Nov; 30(11):1831-1839. PMID: 31987090.
      Citations:    
    39. Porter A, Natsuhara M, Daniels GA, Patel SP, Sacco AG, Bykowski J, Banks KC, Cohen EEW. Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Transl Cancer Res. 2020 Jan; 9(1):203-209. PMID: 35117174; PMCID: PMC8798156.
      Citations: 13     
    40. Pai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, Baste N, Clayburgh D, Lipworth L, Resteghini C, Shara N, Fujii T, Zhang J, Stokes M, Wang H, Twumasi-Ankrah P, Wildsmith S, Khaliq A, Melillo G, Shire N. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Transl Med. 2019 12 26; 17(1):429. PMID: 31878938; PMCID: PMC6933901.
      Citations: 5     Fields:    Translation:Humans
    41. Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Res. 2020 02 15; 80(4):732-746. PMID: 31848196; PMCID: PMC7024675.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    42. Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, Chung CH, Chen Y, Huang B, Davis CB, Toffalorio F, Thall A, Powell SF. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019 12 04; 7(1):342. PMID: 31801624; PMCID: PMC6894203.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    43. Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, Li P, Dechaphunkul A, Kumar V, Kamble K, Li W, Kandil A, Cohen EEW, Geng Y, Zografos E, Tang PZ. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Ann Oncol. 2019 11 01; 30(11):1831-1839. PMID: 31501887; PMCID: PMC6927323.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    44. Vitzthum LK, Park H, Zakeri K, Bryant AK, Feng C, Shen H, Cohen EEW, Murphy JD, Mell LK. Selection of Head and Neck Cancer Patients for Intensive Therapy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):157-166. PMID: 31580929.
      Citations: 3     Fields:    Translation:Humans
    45. Haddad R, Clement PM, Cupissol D, Licitra L, Melichar B, Rauch D, Cohen EEW, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T, Guigay J, Keilholz U, Fayette J, de Souza Viana L, Rolland F, Geoffrois L, Kornek G, Ribaldo Nicolau U, Zanetta-Devauges S, Machiels JP. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91. PMID: 31450171.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    46. Burtness B, Haddad R, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW, LUX-Head & Neck 2 investigators, Dinis J, Trigo J, Martins Segalla JG, Nicolau UR. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA Oncol. 2019 Aug 01; 5(8):1170-1180. PMID: 31194247; PMCID: PMC6567846.
      Citations: 16     Fields:    
    47. Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 07 15; 7(1):184. PMID: 31307547; PMCID: PMC6632213.
      Citations: 293     Fields:    Translation:HumansCTClinical Trials
    48. Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491. PMID: 30936880; PMCID: PMC6431643.
      Citations: 14     Fields:    Translation:HumansCells
    49. Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223. PMID: 30814108; PMCID: PMC6635035.
      Citations: 71     Fields:    Translation:HumansAnimals
    50. Bryant AK, Sojourner EJ, Vitzthum LK, Zakeri K, Shen H, Nguyen C, Murphy JD, Califano JA, Cohen EEW, Mell LK. Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1393-1399. PMID: 29878161; PMCID: PMC6292787.
      Citations: 27     Fields:    Translation:HumansPHPublic Health
    51. Cohen EEW, Le Tourneau C, Licitra L, Ahn MJ, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ, KEYNOTE-040 investigators, Soulières D, Dinis J, Soria A, Machiels JP, Mach N. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 01 12; 393(10167):156-167. PMID: 30509740.
      Citations: 666     Fields:    Translation:HumansCTClinical Trials
    52. Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1583-1588. PMID: 29931076; PMCID: PMC6248084.
      Citations: 58     Fields:    Translation:Humans
    53. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317. PMID: 29948021; PMCID: PMC6739841.
      Citations: 10     Fields:    Translation:HumansCells
    54. Akthar AS, Hellekson CD, Ganai S, Hahn OM, Maggiore RJ, Cohen EE, Posner MC, Chmura SJ, Howard AR, Golden DW. Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ. 2018 06; 33(3):622-626. PMID: 27873183.
      Citations: 10     Fields:    Translation:Humans
    55. Ferrarotto R, William WN, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90. PMID: 29909907.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    56. Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140. PMID: 29635316; PMCID: PMC5961254.
      Citations: 55     Fields:    Translation:Humans
    57. Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22. PMID: 29706184.
      Citations: 18     Fields:    Translation:Humans
    58. Lingen MW, Tampi MP, Urquhart O, Abt E, Agrawal N, Chaturvedi AK, Cohen E, D'Souza G, Gurenlian J, Kalmar JR, Kerr AR, Lambert PM, Patton LL, Sollecito TP, Truelove E, Banfield L, Carrasco-Labra A. Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association. J Am Dent Assoc. 2017 11; 148(11):797-813.e52. PMID: 29080605; PMCID: PMC7366378.
      Citations: 26     Fields:    Translation:Humans
    59. Lingen MW, Abt E, Agrawal N, Chaturvedi AK, Cohen E, D'Souza G, Gurenlian J, Kalmar JR, Kerr AR, Lambert PM, Patton LL, Sollecito TP, Truelove E, Tampi MP, Urquhart O, Banfield L, Carrasco-Labra A. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. J Am Dent Assoc. 2017 10; 148(10):712-727.e10. PMID: 28958308.
      Citations: 54     Fields:    Translation:Humans
    60. Cohen EEW, Licitra LF, Burtness B, Gauler T, Clement PM, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Merlano MC, Dupuis N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Fayette J, Grau JJ, Geoffrois L, Krämer N, Machiels JH. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017 Oct 01; 28(10):2526-2532. PMID: 28961833; PMCID: PMC5834024.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    61. Sacco AG, Cohen EE. Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. Cancer. 2017 11 15; 123(22):4310-4313. PMID: 28950413.
      Citations:    Fields:    Translation:HumansCells
    62. Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Carson DA, Hayashi T, Cohen EE. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18). PMID: 28931759; PMCID: PMC5621908.
      Citations: 141     Fields:    Translation:HumansAnimalsCells
    63. Reynolds KL, Bedard PL, Lee SH, Lin CC, Cohen E, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ, Tabernero J, Alsina M, Baselga J. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646. PMID: 28899363; PMCID: PMC5596462.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    64. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723. PMID: 28420725; PMCID: PMC5737735.
      Citations: 58     Fields:    Translation:Humans
    65. Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, Harrison LB, Lu C, Moeller BJ, Quon H, Rocco JW, Sturgis EM, Tishler RB, Trotti A, Waldron J, Eisbruch A. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017 Jul - Aug; 7(4):246-253. PMID: 28428019.
      Citations: 26     Fields:    Translation:Humans
    66. Ben Aharon I, Limon D, Cohen E, Popovtzer A, Vidal L. Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis. Cancer J. 2017 Mar/Apr; 23(2):79-83. PMID: 28410291.
      Citations: 13     Fields:    Translation:Humans
    67. Tota JE, Anderson WF, Coffey C, Califano J, Cozen W, Ferris RL, St John M, Cohen EE, Chaturvedi AK. Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. Oral Oncol. 2017 04; 67:146-152. PMID: 28351569.
      Citations: 65     Fields:    Translation:Humans
    68. Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, Perkins AS, Bonifaci N, Skowron M, Serrat X, Brunet J, Barretina MP, Gil M, Falo C, Morilla I, Pernas S, Ballester R, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Cordero A, Palomero L, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, Puente XS, Casanovas O, Graupera M, Saez-Rodriguez J, Esteller M, Sierra A, Matheu A, Carracedo A, Nanjundan M, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA, Català I, Lozano J, García N, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Cerón J, Fernández A, Plà MJ, Andreu X, Seguí MA, Castellà E, Sánchez-Mut JV, Sánchez-Céspedes M, Gómez-Miragaya J, Gómez A, López-Bigas N, Valdés-Mas R, Viñals F, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Martín-Martín N, González-Suárez E, Cortés J, Lázaro C. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 05 11; 36(19):2737-2749. PMID: 27991928; PMCID: PMC5442428.
      Citations: 18     Fields:    Translation:HumansCells
    69. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271. PMID: 27906454; PMCID: PMC5705038.
      Citations: 25     Fields:    Translation:Humans
    70. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen EE, Varner JA. PI3K? is a molecular switch that controls immune suppression. Nature. 2016 11 17; 539(7629):437-442. PMID: 27642729; PMCID: PMC5479689.
      Citations: 561     Fields:    Translation:HumansAnimalsCells
    71. Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS, Schöffski P. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864. PMID: 27525386.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    72. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82. PMID: 27460442; PMCID: PMC5532535.
      Citations: 168     Fields:    Translation:HumansCTClinical Trials
    73. Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9. PMID: 27511844.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    74. Abbott DM, Cohen EE, Sadeghi N, Stein KD, Erb NL. Considering the survivorship care needs of head and neck cancer survivors. Oral Oncol. 2016 06; 57:61-2. PMID: 27130576.
      Citations:    Fields:    Translation:Humans
    75. Clement PM, Gauler T, Haddad RI, Licitra LF, Tahara M, Cohen EE, Guigay J, Caponigro F, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB, LUX-H&N 1 investigators, Machiels JP, Fayette J, Cupissol D, Grau JJ, de Castro G, de Souza Viana L, Keilholz U. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 08; 27(8):1585-93. PMID: 27084954; PMCID: PMC4959921.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    76. Chen P, Mancini M, Sonis ST, Fernandez-Martinez J, Liu J, Cohen EE, Toback FG. A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS One. 2016; 11(4):e0152995. PMID: 27049860; PMCID: PMC4822960.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    77. Cohen EE, LaMonte SJ, Erb NL, Beckman KL, Sadeghi N, Hutcheson KA, Stubblefield MD, Abbott DM, Fisher PS, Stein KD, Lyman GH, Pratt-Chapman ML. American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016 05; 66(3):203-39. PMID: 27002678.
      Citations: 223     Fields:    Translation:Humans
    78. Yamaguchi K, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, Gutkind JS, Iglesias-Bartolomé R. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 08; 7(10):10696-709. PMID: 26882569; PMCID: PMC4905432.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    79. Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13. PMID: 26884588.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    80. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011. PMID: 26846975; PMCID: PMC5075244.
      Citations: 58     Fields:    Translation:Humans
    81. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16. PMID: 26540028; PMCID: PMC4771491.
      Citations: 68     Fields:    Translation:Humans
    82. Boero IJ, Paravati AJ, Xu B, Cohen EE, Mell LK, Le QT, Murphy JD. Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol. 2016 Mar 01; 34(7):684-90. PMID: 26729432; PMCID: PMC4872027.
      Citations: 62     Fields:    Translation:Humans
    83. Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23. PMID: 26598548; PMCID: PMC4722891.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    84. Yeung KT, Cohen EE. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21(24):5420-6. PMID: 26487760.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    85. Sacco AG, Cohen EE. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 Oct 10; 33(29):3305-13. PMID: 26351341.
      Citations: 164     Fields:    Translation:Humans
    86. O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9. PMID: 26199386; PMCID: PMC4677671.
      Citations: 1     Fields:    Translation:Humans
    87. Sasaki MM, Skol AD, Bao R, Rhodes LV, Chambers R, Vokes EE, Cohen EE, Onel K. Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1222-8. PMID: 26014803; PMCID: PMC4526396.
      Citations: 14     Fields:    Translation:Humans
    88. Haddad RI, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Caponigro F, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE, LUX-H&N 1 investigators, Machiels JP, Fayette J, Grau JJ, Guigay J, de Castro G, de Souza Viana L, Keilholz U. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):583-94. PMID: 25892145.
      Citations: 157     Fields:    Translation:HumansCTClinical Trials
    89. Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74. PMID: 25769300; PMCID: PMC4681575.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    90. Raju SC, Hauff SJ, Lemieux AJ, Orosco RK, Gross AM, Nguyen LT, Savariar E, Moss W, Whitney M, Cohen EE, Lippman SM, Tsien RY, Ideker T, Advani SJ, Nguyen QT. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. Oral Oncol. 2015 May; 51(5):470-5. PMID: 25735654; PMCID: PMC4427339.
      Citations: 7     Fields:    Translation:HumansCells
    91. Price KA, Cohen EE. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncol. 2015 May; 51(5):399-408. PMID: 25725588.
      Citations: 11     Fields:    Translation:Humans
    92. Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968. PMID: 25667282.
      Citations:    Fields:    Translation:Humans
    93. Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE, Pelosi G. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Lett. 2015 Apr 10; 359(2):269-74. PMID: 25641339.
      Citations: 5     Fields:    Translation:Humans
    94. Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F, Cohen EE. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec; 10(4):501-8. PMID: 25559287; PMCID: PMC4492891.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    95. Gross AM, Cohen EE. Towards a personalized treatment of head and neck cancer. Am Soc Clin Oncol Educ Book. 2015; 28-32. PMID: 25993138.
      Citations: 1     Fields:    Translation:Humans
    96. Xu B, Boero IJ, Hwang L, Le QT, Moiseenko V, Sanghvi PR, Cohen EE, Mell LK, Murphy JD. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015 Apr 15; 121(8):1303-11. PMID: 25537836; PMCID: PMC4774546.
      Citations: 64     Fields:    Translation:Humans
    97. Simpson DR, Mell LK, Cohen EE. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2015 Apr; 51(4):291-8. PMID: 25532816.
      Citations: 78     Fields:    Translation:Humans
    98. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY, Brägelmann J. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81. PMID: 25492084.
      Citations: 177     Fields:    Translation:HumansCells
    99. Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014 Nov 29; 15:469. PMID: 25432788; PMCID: PMC4289298.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    100. Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EEW, Seiwert TY, Haraf DJ, Vokes EE. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205. PMID: 25361984.
      Citations: 4     Fields:    Translation:HumansCells
    101. Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89. PMID: 25336084.
      Citations: 6     Fields:    Translation:Humans
    102. Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 12; 74(6):1261-70. PMID: 25315258; PMCID: PMC4236619.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    103. Khattri A, Zuo Z, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, White KP, Vokes EE, Seiwert TY, Brägelmann J. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8. PMID: 25255959.
      Citations: 11     Fields:    Translation:HumansCells
    104. Gallop K, Kerr C, Simmons S, McIver B, Cohen EE. A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases. Qual Life Res. 2015 Feb; 24(2):325-38. PMID: 25106505.
      Citations: 15     Fields:    Translation:Humans
    105. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. PMID: 25086664; PMCID: PMC4146706.
      Citations: 72     Fields:    Translation:HumansCells
    106. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS, Brägelmann J. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41. PMID: 25056374; PMCID: PMC4305034.
      Citations: 332     Fields:    Translation:HumansCells
    107. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43. PMID: 25049329; PMCID: PMC4876357.
      Citations: 179     Fields:    Translation:HumansCTClinical Trials
    108. Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112. PMID: 25019640; PMCID: PMC4096922.
      Citations: 6     Fields:    Translation:HumansCells
    109. Licitra LF, Haddad RI, Tahara M, Cohen EE, Machiels JP. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014 Jun 28; 14:473. PMID: 24973959; PMCID: PMC4079914.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    110. Seiwert TY, Cupissol D, Del Campo JM, Clement PM, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EEW, Fayette J, Hitt R. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014 Sep; 25(9):1813-1820. PMID: 24928832; PMCID: PMC4143093.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    111. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 09 01; 120(17):2694-703. PMID: 24844950.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    112. Cohen E, Lee A. Editorial for special issue on nasopharynx cancer. Oral Oncol. 2014 May; 50(5):325. PMID: 24726206.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    113. Kamaria M, Shea CR, Chin RK, Cohen EE, Maggiore R, Bolotin D. Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab. Clin Exp Dermatol. 2014 Jul; 39(5):604-7. PMID: 24758726.
      Citations: 3     Fields:    Translation:Humans
    114. Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, Gauler TC. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1227-39. PMID: 24714973.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    115. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. PMID: 24637941; PMCID: PMC4165641.
      Citations: 6     Fields:    Translation:Humans
    116. Kuo WL, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M, Macleod KF, Cohen EE. p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One. 2014; 9(3):e90171. PMID: 24599075; PMCID: PMC3943907.
      Citations: 16     Fields:    Translation:HumansCells
    117. Hollebecque A, Cohen EE, Massard C, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC, Houédé N, Italiano A. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar; 50(5):876-84. PMID: 24456794.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    118. Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4. PMID: 24134948.
      Citations: 9     Fields:    Translation:Humans
    119. Cohen E, Chen AY, Ferris RL, Lee A, Bernier J. Open Access in biomedical sciences: what the current turning point means more specifically to Oral Oncology contributors and readers. Oral Oncol. 2013 Oct; 49(10):985-6. PMID: 24045003.
      Citations:    Fields:    Translation:Humans
    120. Schlumberger MJ, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI, Elisei R, Müller SP, Schöffski P. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46. PMID: 24002501; PMCID: PMC4164813.
      Citations: 436     Fields:    Translation:HumansCTClinical Trials
    121. Cohen EE, Ahmed O, Kocherginsky M, Shustakova G, Kistner-Griffin E, Salama JK, Yefremenko V, Novosad V. Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. Oral Oncol. 2013 Oct; 49(10):1025-31. PMID: 23988569; PMCID: PMC3797568.
      Citations: 4     Fields:    Translation:Humans
    122. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. PMID: 23900000; PMCID: PMC3755935.
      Citations: 5     Fields:    Translation:HumansCells
    123. Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EEW, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E. A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. Oral Oncol. 2013 Sep; 49(9):970-976. PMID: 23845699; PMCID: PMC4456032.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    124. Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen EE. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. J Geriatr Oncol. 2013 Oct; 4(4):327-33. PMID: 24472475; PMCID: PMC4413907.
      Citations: 9     Fields:    Translation:Humans
    125. de Souza JA, de Lima Lopes G, Cohen EE. Pharmacoeconomic issues in head and neck oncology. Curr Opin Oncol. 2013 May; 25(3):213-7. PMID: 23508082.
      Citations: 3     Fields:    Translation:Humans
    126. Sivasithamparam J, Visk CA, Cohen EE, King AC. Modifiable risk behaviors in patients with head and neck cancer. Cancer. 2013 Jul 01; 119(13):2419-26. PMID: 23575663; PMCID: PMC3687000.
      Citations: 15     Fields:    Translation:HumansCells
    127. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67. PMID: 23553850; PMCID: PMC3674138.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    128. Yang JC, Reguart N, Barinoff J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Cohen EE, Köhler J, Wolf J. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013 Jun; 13(6):729-36. PMID: 23506556.
      Citations: 42     Fields:    Translation:Humans
    129. Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY, Brägelmann J. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. PMID: 23490885.
      Citations: 15     Fields:    Translation:HumansCells
    130. Kim DH, Vitol EA, Liu J, Balasubramanian S, Gosztola DJ, Cohen EE, Novosad V, Rozhkova EA. Stimuli-responsive magnetic nanomicelles as multifunctional heat and cargo delivery vehicles. Langmuir. 2013 Jun 18; 29(24):7425-32. PMID: 23351096.
      Citations: 25     Fields:    
    131. Saloura V, Langerman A, Rudra S, Chin R, Cohen EE. Multidisciplinary care of the patient with head and neck cancer. Surg Oncol Clin N Am. 2013 Apr; 22(2):179-215. PMID: 23453331.
      Citations: 17     Fields:    Translation:Humans
    132. Wu K, Cohen EE, House LK, Zhang W, Ratain MJ, Bies RR, Ramírez J. Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer. CPT Pharmacometrics Syst Pharmacol. 2012 Dec 05; 1:e17. PMID: 23887441; PMCID: PMC3600722.
      Citations: 10     Fields:    
    133. Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EE. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68. PMID: 23200321; PMCID: PMC3661759.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    134. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76. PMID: 23104721; PMCID: PMC3662388.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    135. Golden DW, Rudra S, Witt ME, Nwizu T, Cohen EE, Blair E, Stenson KM, Vokes EE, Haraf DJ. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82. PMID: 23102863.
      Citations: 7     Fields:    Translation:Humans
    136. Nagilla M, Brown RL, Cohen EE. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012 Nov; 29(11):925-34. PMID: 23104465.
      Citations: 18     Fields:    Translation:Humans
    137. Haigentz M, Cohen EE, Wolf GT, Eisbruch A, Ferlito A, Strojan P. The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2012 Nov; 48(11):1065-7. PMID: 22981388.
      Citations: 8     Fields:    Translation:Humans
    138. Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93. PMID: 22872575; PMCID: PMC4410974.
      Citations: 33     Fields:    Translation:HumansAnimalsCTClinical Trials
    139. Nwizu T, Ghi MG, Cohen EE, Paccagnella A. The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012 Jul; 22(3):198-206. PMID: 22687944.
      Citations: 5     Fields:    Translation:Humans
    140. Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030. PMID: 22621836.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    141. Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, Graham FJ, Hujoel PP, Kalmar JR, Koch WM, Lambert PM, Lingen MW, Oettmeier BW, Patton LL, Perkins D, Reid BC, Sciubba JJ, Tomar SL, Wyatt AD, Aravamudhan K, Frantsve-Hawley J, Cleveland JL, Meyer DM, American Dental Association Council on Scientific Affairs Expert Panel on Screening for Oral Souamou. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. Tex Dent J. 2012 May; 129(5):491-507. PMID: 22779205.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    142. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92. PMID: 22513208.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    143. Cohen EE. New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6. PMID: 22706487.
      Citations:    Fields:    Translation:Humans
    144. Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P, Cohen EE. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol. 2012 Aug; 48(8):723-9. PMID: 22414289.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    145. Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 2012 Mar; 13(1):35-46. PMID: 22252884.
      Citations: 91     Fields:    Translation:HumansCells
    146. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43. PMID: 22371453; PMCID: PMC4467891.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    147. Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, Cohen EE, Xing HR, Lussier YA. Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012 Jan; 8(1):e1002350. PMID: 22291585; PMCID: PMC3266878.
      Citations: 56     Fields:    Translation:Humans
    148. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr 01; 18(7):2056-65. PMID: 22241789; PMCID: PMC5157199.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    149. Cohen EE, Ferreira MB, Lima JP. Novel targeted therapies in head and neck cancer. Expert Opin Investig Drugs. 2012 Mar; 21(3):281-95. PMID: 22239178.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    150. Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8. PMID: 22100149.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    151. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70. PMID: 22020702.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    152. Wu K, Janisch L, Karrison T, House LK, Innocenti F, Cohen EE, Ratain MJ, Ramírez J. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32. PMID: 21861128; PMCID: PMC3259680.
      Citations: 2     Fields:    Translation:Humans
    153. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31. PMID: 21791072; PMCID: PMC3189162.
      Citations: 15     Fields:    Translation:Humans
    154. Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8. PMID: 21671479.
      Citations: 22     Fields:    Translation:Humans
    155. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Ratain MJ, Salgia R, Müller T. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. PMID: 21606412; PMCID: PMC3646303.
      Citations: 223     Fields:    Translation:HumansCTClinical Trials
    156. Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45. PMID: 21544895.
      Citations: 12     Fields:    Translation:Humans
    157. Ferreira MB, De Souza JA, Cohen EE. Role of molecular markers in the management of head and neck cancers. Curr Opin Oncol. 2011 May; 23(3):259-64. PMID: 21358329.
      Citations: 15     Fields:    Translation:HumansCells
    158. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011 Jun 01; 17(11):3841-9. PMID: 21531811.
      Citations: 76     Fields:    Translation:Humans
    159. Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer. 2011 Apr 04; 2:193-9. PMID: 21509149; PMCID: PMC3079916.
      Citations: 77     
    160. Gangadhar TC, Cohen EE, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, Fleming GF, Ratain MJ. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63. PMID: 21447721; PMCID: PMC3077032.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    161. Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, Jones RB, Rosner MR, Cohen EE. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82. PMID: 21438065.
      Citations: 8     Fields:    Translation:AnimalsCells
    162. Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9. PMID: 21439817; PMCID: PMC4116678.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    163. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EEW. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507. PMID: 21385883.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    164. Langerman A, Patel RM, Cohen EE, Blair EA, Stenson KM. Airway management before chemoradiation for advanced head and neck cancer. Head Neck. 2012 Feb; 34(2):254-9. PMID: 21384461.
      Citations: 6     Fields:    Translation:Humans
    165. Cohen EE, Schilsky RL. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5. PMID: 21372026.
      Citations:    Fields:    Translation:Humans
    166. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9. PMID: 21330337.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    167. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72. PMID: 21497773; PMCID: PMC3079878.
      Citations: 35     Fields:    Translation:HumansCells
    168. Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34. PMID: 21173372.
      Citations: 8     Fields:    Translation:Humans
    169. Choe KS, Salama JK, Stenson KM, Blair EA, Witt ME, Cohen EE, Haraf DJ, Vokes EE. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21. PMID: 20934766.
      Citations: 3     Fields:    Translation:Humans
    170. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, Cohen EE. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24. PMID: 20876745; PMCID: PMC2953602.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    171. de Souza JA, Cohen EE. [18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality. J Clin Oncol. 2010 Oct 01; 28(28):e516; author reply e517. PMID: 20606097.
      Citations: 1     Fields:    Translation:Humans
    172. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43. PMID: 20498391; PMCID: PMC2903330.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    173. Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, Graham FJ, Hujoel PP, Kalmar JR, Koch WM, Lambert PM, Lingen MW, Oettmeier BW, Patton LL, Perkins D, Reid BC, Sciubba JJ, Tomar SL, Wyatt AD, Aravamudhan K, Frantsve-Hawley J, Cleveland JL, Meyer DM, American Dental Association Council on Scientific Affairs Expert Panel on Screening for Oral Squamou. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc. 2010 May; 141(5):509-20. PMID: 20436098.
      Citations: 83     Fields:    Translation:HumansPHPublic Health
    174. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010 May 01; 16(9):2489-95. PMID: 20406834; PMCID: PMC2887084.
      Citations: 53     Fields:    Translation:Humans
    175. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64. PMID: 20215515; PMCID: PMC2881662.
      Citations: 45     Fields:    Translation:HumansCells
    176. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):358-65. PMID: 20086114; PMCID: PMC2846615.
      Citations: 29     Fields:    Translation:HumansCells
    177. Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9. PMID: 19856305.
      Citations: 31     Fields:    Translation:Humans
    178. Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20. PMID: 19933920.
      Citations: 54     Fields:    Translation:Humans
    179. de Souza JA, Cohen EE. Personalizing cancer care: updates on head and neck cancer. Expert Rev Anticancer Ther. 2009 Sep; 9(9):1219-22. PMID: 19761425.
      Citations:    Fields:    Translation:Humans
    180. Choong NW, Kozloff M, Taber D, Hu HS, Wade J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83. PMID: 19649772.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    181. Vidal L, Tsao MS, Pond GR, Cohen EE, Cohen RB, Chen EX, Agulnik M, Hotte S, Winquist E, Laurie S, Hayes DN, Ho J, Dancey J, Siu LL. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck. 2009 Aug; 31(8):1006-12. PMID: 19309723; PMCID: PMC2711990.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    182. Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21. PMID: 19340870.
      Citations: 14     Fields:    Translation:Humans
    183. Cooper JB, Cohen EE. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck. 2009 Aug; 31(8):1086-94. PMID: 19378324.
      Citations: 23     Fields:    Translation:HumansCells
    184. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60. PMID: 19586795; PMCID: PMC2749898.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    185. Yefremenko V, Gordiyenko E, Shustakova G, Fomenko Y, Datesman A, Wang G, Pearson J, Cohen EE, Novosad V. A broadband imaging system for research applications. Rev Sci Instrum. 2009 May; 80(5):056104. PMID: 19485541; PMCID: PMC2719480.
      Citations: 1     Fields:    
    186. Chen L, Cohen EE. Surrogate endpoints in head and neck cancer. Lancet Oncol. 2009 Apr; 10(4):309-10. PMID: 19341966.
      Citations:    Fields:    Translation:Humans
    187. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31. PMID: 19318576; PMCID: PMC2871252.
      Citations: 122     Fields:    Translation:HumansAnimalsCells
    188. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71. PMID: 19289630.
      Citations: 122     Fields:    Translation:HumansCTClinical Trials
    189. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57. PMID: 19201650; PMCID: PMC2768532.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    190. Kocherginsky M, Cohen EE, Karrison T. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9. PMID: 19384693.
      Citations: 4     Fields:    Translation:Humans
    191. Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 01; 69(1):65-74. PMID: 19117988; PMCID: PMC2746005.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    192. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes EE, Haraf DJ. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5. PMID: 18936351.
      Citations: 20     Fields:    Translation:Humans
    193. Cohn AB, Lang PO, Agarwal JP, Peng SL, Alizadeh K, Stenson KM, Haraf DJ, Cohen EEW, Vokes EE, Gottlieb LJ. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132. PMID: 18594395.
      Citations: 7     Fields:    Translation:Humans
    194. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13. PMID: 18541897; PMCID: PMC4859206.
      Citations: 233     Fields:    Translation:HumansCTClinical Trials
    195. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94. PMID: 18539617.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    196. Vokes EE, Cohen EE, Grandis JR. Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7. PMID: 18544434.
      Citations:    Fields:    Translation:Humans
    197. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008 Jun; 35(3):274-85. PMID: 18544442.
      Citations: 27     Fields:    Translation:Humans
    198. Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun; 3(6):631-6. PMID: 18520803.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    199. Faoro L, Cohen EE, Govindan R, Kozloff MF, Hoffman PC, Maitland ML, Verel K, Szeto L, Salgia R, Vokes EE. Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):19130. PMID: 27947490.
      Citations:    
    200. Vokes EE, Seiwert TY, Blair E, Cohen EE, Salama J, Villaflor VM, Witt M, Kovacevic M, Stenson K, Haraf D. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6067. PMID: 27947830.
      Citations:    
    201. Gangadhar T, Cohen EE, Janisch L, House LK, Undevia SD, Fleming GF, Maitland ML, Ramirez J, Ratain MJ. A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):2545. PMID: 27947936.
      Citations:    
    202. Ratain MJ, Benedetti FM, Janisch L, Khor S, Schilsky RL, Cohen EE, Maitland ML, Elias L, LoRusso PM. A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3581. PMID: 27949674.
      Citations:    
    203. Hartford CM, Cohen EE, Fox-Kay K, Ott J, Jiang X, Kocherginsky M, Ratain MJ. Addition of grapefruit juice (GJ) to increase the bioavailability of high-dose weekly rapamcyin (R). J Clin Oncol. 2008 May 20; 26(15_suppl):3587. PMID: 27949683.
      Citations:    
    204. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade Iii JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):6025. PMID: 27950549.
      Citations:    
    205. Villaflor VM, Cohen EE, Haraf D, Stenson K, Blair E, Salama J, Portugal L, Williams R, Thomas A, Gomez-Abuin G, Vokes EE. Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients. J Clin Oncol. 2008 May 20; 26(15_suppl):6030. PMID: 27950566.
      Citations:    
    206. Choong NW, Cohen EE, Kozloff MF, Taber D, Wade Iii JL, Hu S, Ivy SP, Nichols K, Dekker A, Vokes EE. Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2008 May 20; 26(15_suppl):6064. PMID: 27950584.
      Citations:    
    207. Seiwert TY, Cohen EE, Wang X, Kocherginsky M, Bhayani M, Stenson K, Finn S, O'Regan EM, Weaver D, Vokes EE. Use of systematic analysis of DNA repair pathways in head and neck cancer (HNC) to identify XPF as a novel predictor of induction response, and pMK2 relationship to chemoradiotherapy. J Clin Oncol. 2008 May 20; 26(15_suppl):6003. PMID: 27950665.
      Citations:    
    208. Knab BR, Salama JK, Solanki A, Stenson KM, Cohen EE, Witt ME, Haraf DJ, Vokes EE. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4. PMID: 18467314.
      Citations: 9     Fields:    Translation:Humans
    209. Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, Delgado J, Tretiakova M, Joseph L, Hart J, Cohen EE, Aluri L, Fichera A, Bissonnette M. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008 Apr 15; 14(8):2253-62. PMID: 18413814.
      Citations: 31     Fields:    Translation:Animals
    210. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41. PMID: 18375903.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    211. Cohen EE. mTOR: the mammalian target of replication. J Clin Oncol. 2008 Jan 20; 26(3):348-9. PMID: 18202406.
      Citations: 7     Fields:    Translation:Humans
    212. Keswani RN, Chumsangsri A, Mustafi R, Delgado J, Cohen EE, Bissonnette M. Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Dis Esophagus. 2008; 21(6):514-21. PMID: 18840136.
      Citations: 10     Fields:    Translation:HumansCells
    213. Ahmed SM, Cohen EE. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets. 2007 Nov; 7(7):666-73. PMID: 18045071.
      Citations: 9     Fields:    Translation:Humans
    214. Yount S, List M, Du H, Yost K, Bode R, Brockstein B, Argiris A, Vokes E, Cohen EE, Campbell B, Valenzuela V, George J, Egan R, Chen J, Meddis D, Cella D. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26. PMID: 17922221.
      Citations: 11     Fields:    Translation:Humans
    215. Seiwert TY, Cohen EE, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44. PMID: 17882655.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    216. Cohen EE. A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4317-9. PMID: 17671110.
      Citations:    Fields:    Translation:HumansCells
    217. Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8. PMID: 17635950.
      Citations: 24     Fields:    Translation:Humans
    218. Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84. PMID: 17293229.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    219. Choong NW, Cohen EE. Forthcoming receptor tyrosine kinase inhibitors. Expert Opin Ther Targets. 2006 Dec; 10(6):793-7. PMID: 17105367.
      Citations: 4     Fields:    Translation:Humans
    220. Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44. PMID: 16849759; PMCID: PMC4430103.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    221. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70. PMID: 16760642.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    222. Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303. PMID: 16778206.
      Citations: 37     Fields:    Translation:HumansCells
    223. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006 Jun 10; 24(17):2659-65. PMID: 16763280.
      Citations: 46     Fields:    Translation:HumansCells
    224. Stenson KM, Huo D, Blair E, Cohen EE, Argiris A, Haraf DJ, Vokes EE. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6. PMID: 16481805.
      Citations: 9     Fields:    Translation:Humans
    225. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24. PMID: 16322304.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    226. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. PMID: 16299242.
      Citations: 50     Fields:    Translation:HumansCells
    227. Choong NW, Cohen EE. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006 Jan; 57(1):25-43. PMID: 16207530.
      Citations: 17     Fields:    Translation:HumansCells
    228. Vokes EE, Cohen EE, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, Kozloff MF, Dancey J, Dekker A. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol. 2005 Jun; 23(16_suppl):5504. PMID: 27945465.
      Citations:    
    229. Cohen EE, Haraf DJ, Stenson KM, Blair E, Brockstein BE, Mauer AM, Dekker A, Williams R, Lester E, Vokes EE. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial. J Clin Oncol. 2005 Jun; 23(16_suppl):5506. PMID: 27945467.
      Citations:    
    230. Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005 Apr 25; 92(8):1341-8. PMID: 15846296; PMCID: PMC2361996.
      Citations: 98     Fields:    Translation:Humans
    231. Cohen EE. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol. 2004 Dec; 31(6):755-68. PMID: 15599853.
      Citations: 2     Fields:    Translation:HumansCells
    232. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83. PMID: 15547705.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    233. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52. PMID: 15117998.
      Citations: 67     Fields:    Translation:Humans
    234. Cohen EE, Vokes EE. Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):81-90. PMID: 15005282.
      Citations: 2     Fields:    Translation:Humans
    235. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15; 21(24):4546-52. PMID: 14597742; PMCID: PMC4523388.
      Citations: 38     Fields:    Translation:HumansCellsCTClinical Trials
    236. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7. PMID: 12743152.
      Citations: 144     Fields:    Translation:HumansCTClinical Trials
    237. Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71. PMID: 12367795.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    238. Cohen EE, Vokes EE. Searching for a standard. J Clin Oncol. 2002 Jan 15; 20(2):359-61. PMID: 11786560.
      Citations:    Fields:    Translation:Humans
    239. Cohen EE, Rudin CM. ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs. 2001 Dec; 2(12):1770-5. PMID: 11892945.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    240. Cohen EE, Vokes EE. Esophageal cancer therapy: a decade of inertia. Cancer J. 2001 Sep-Oct; 7(5):369-71. PMID: 11693893.
      Citations:    Fields:    Translation:Humans
    241. Cohen EE, Stadler WM. Treatment of metastatic urothelial cancer in the post-MVAC era. World J Urol. 2001 Apr; 19(2):126-32. PMID: 11374315.
      Citations:    Fields:    Translation:Humans
    242. Cohen EE, Vokes EE. Locally advanced non-small cell lung cancer. Curr Treat Options Oncol. 2001 Feb; 2(1):27-42. PMID: 12057138.
      Citations:    Fields:    Translation:Humans
    Cohen's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (656)
    Explore
    _
    Co-Authors (58)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _